Cytarabine Added to Interferon Improves the Cost-Effectiveness of Initial Therapy for Patients with Early Chronic Phase Chronic Myelogenous Leukemia

References

• Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H. M. The biology of chronic myeloid leukemia. New England Journal of Medicine 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Faderl S., Talpaz M., Estrov Z., Kantarjian H. M. Chronic myelogenous leukemia: biology and therapy. Annals of Internal Medicine 1999; 131: 207–219
   PubMed Web of Science ®Google Scholar
• Dazzi F., Capelli D., Hasserjian R., Cotter F., Corbo M., Poletti A., Chinswangwatanakul W., Goldman J. M., Gordon M. Y. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 1998; 92: 1390–1396
   PubMed Web of Science ®Google Scholar
• Warmuth M., Danhauser-Riedl S., Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Annals of Hematology 1999; 78: 49–64
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Annals of Internal Medicine 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Giles F. J., O'Brien S. M., Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematology and Oncology Clinics of North America 1998; 12: 31–80
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541–1548
   PubMed Web of Science ®Google Scholar
• Shepherd P. C., Richards S. M., Allan N. C. Progress with interferon in CML-results of the MRC UK CML III study. Bone Marrow Transplantation 1996; 17(Suppl 3)S15–S18
   PubMedGoogle Scholar
• Allan N. C., Richards S. M., Shepherd P. C. UK Medical Research Council randomised, multicentre trial of interferon-alpha nl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Richards S. M. Interferon-alpha: results from randomized trials. Baillieres Clinics in Haematology 1997; 10: 307–318
   PubMedGoogle Scholar
• Ohnishi K., Ohno R., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., Dohy H., Mizoguchi H., Miyawaki S., Tsubaki K., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906–916
   PubMed Web of Science ®Google Scholar
• Hasford J., Baccarani M., Hehlmann R., Anseri H., Tura S., Zuffa E. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha [letter]. Blood 1996; 87: 5384–5391
   PubMed Web of Science ®Google Scholar
• Silver R. T., Woolf S. H., Hehimann R., Appelbaum F. R., Anderson J., Bennett C., Goldman J. M., Guilhot F., Kantarjian H. M., Lichtin A. E., Talpaz M., Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536
   PubMed Web of Science ®Google Scholar
• Giles F. J., Aitchison R., Syndercombe-Court D., Schey S., Newland A. C. Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia. Leukemia and Lymphoma 1992; 7: 99–102
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Estey E. H., O'Brien S., Pierce S., Beran M., Roller C., Feldman E., Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. Journal of Clinical Oncology 1992; 10: 772–778
   PubMed Web of Science ®Google Scholar
• Arthur C. K., Ma D. D. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematologica 1993; 89: 15–21
   PubMed Web of Science ®Google Scholar
• Guilhot F., Abgrall J. F., Harousseau J. L., Haulers F., Brice P., Dine G., Tilly H., Ifrah N., Cassasus P., Rochant H., et al. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results. Leukemia and Lymphoma, 11: 181–183
   PubMed Web of Science ®Google Scholar
• Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J. L., Maloisel F., Bouabdallah R., Guyotat D., Cheron N., Nicolini F., Abgrall J. F., Tanzer J. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. New England Journal of Medicine 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., O'Brien S., Smith T. L., Rios M. B., Cortes J., Beran M., Roller C., Giles F. J., Andreeff M., Kornblau S., Giralt S., Keating M. J., Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. Journal of Clinical Oncology 1999; 17: 284–292
   PubMed Web of Science ®Google Scholar
• Kattan M. W., Inoue Y., Giles F. J., Talpaz M., Ozer H., Guilhot F., Zuffa E., Huber S. L., Beck J. R. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Annals of Internal Medicine 1996; 125: 541–548
   PubMed Web of Science ®Google Scholar
• Sacchi S., Kantarjian H. M., O'Brien S., Cortes J., Rios M. B., Giles F. J., Beran M., Koller C. A., Keating M. J., Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632–2641
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Talpaz M., Walters R. S., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. American Journal of Medicine 1987; 83: 445–454
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., O'Brien S. M., Keating M., Beran M., Estey E., Giralt S., Kornblau S., Rios M. B., de Vos D., Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997; 11: 1617–1620
   PubMed Web of Science ®Google Scholar
• Lee S. J., Anasetti C., Kuntz K. M., Patten J., Antin J. H., Weeks J. C. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998; 92: 4047–4052
   PubMed Web of Science ®Google Scholar
• Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Annals of Oncology 1998; 9: 389–396
   PubMed Web of Science ®Google Scholar
• Guilhot F., Dreyfus B., Brizard A., et al. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha2a and hydroxyurea with or without low dose cytosine-arabinoside. Leukemia and Lymphoma 1991; 4: 49–55
   PubMed Web of Science ®Google Scholar
• Rosti G., Bonifazi A., De Vivo G., et al. Cytarabine increases karyotypic response and survival in IFN-α treated chronic myelogenous leukemia patients: results of a national prospective randomized trial of the Italian Cooperative Study Group in CML. Blood 1999; 94(Suppl 1)2669a
   Google Scholar